Cancer Immunotherapy

B7-1 Gene Transfer is a Promising Immunotherapeutic

Published in Cancer Weekly, August 23rd, 1999

B7-1 gene transfer into multiple myeloma patients is a promising anticancer immunotherapeutic.

K. Tarte and colleagues from INSERM, France, sought to evaluate whether tumor cells from patients with multiple myeloma activate allogeneic and autologous T cells. They reported their findings in a recent issue of the Journal of Immunology ( "Induced Expression of B7-1 on Myeloma Cells Following Retroviral Gene Transfer Results in Tumor-Specific Recognition by Cytotoxic T Cells," Journal of Immunology, July 1, 1999;163(1):514-524).

"Results showed that myeloma cells expressed few B7-2 and no B7-1 in six cell lines and primary cells from 11 patients," wrote...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-08-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry